Chemical Compound Review:
CTK2G4683 prop-1-yn-1-amine
Synonyms:
LS-125795, NSC 80642, AKOS006350300, BRN 0773681, AC1L29EB, ...
Youdim,
Amit,
Falach-Yogev,
Am,
Maruyama,
Naoi,
Youdim,
Bar Am,
Yogev-Falach,
Weinreb,
Maruyama,
Naoi,
Amit,
Youdim,
Fridkin,
Zheng,
Groeneveld,
van Muiswinkel,
de Leeuw van Weenen,
Blauw,
Veldink,
Wokke,
van den Berg,
Bär,
Kitani,
Minami,
Yamamoto,
Maruyama,
Kanai,
Ivy,
Carrillo,
Youdim,
Amit,
Bar-Am,
Weinreb,
Yogev-Falach,
Sterling,
Herzig,
Goren,
Finkelstein,
Lerner,
Goldenberg,
Miskolczi,
Molnar,
Rantal,
Tamas,
Toth,
Zagyva,
Zekany,
Finberg,
Lavian,
Gross,
Friedman,
Razin,
Huang,
Krais,
Chorev,
Youdim,
Weinstock,
Youdim,
Weinstock,
- Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Mandel, S., Weinreb, O., Amit, T., Youdim, M.B. Brain Res. Brain Res. Rev. (2005)
- Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Chen, J.J., Swope, D.M. Journal of clinical pharmacology. (2005)
- Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. Bar-Am, O., Weinreb, O., Amit, T., Youdim, M.B. FASEB J. (2005)
- Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Youdim, M.B., Amit, T., Bar-Am, O., Weinreb, O., Yogev-Falach, M. Neurotoxicity research (2006)
- Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Tabakman, R., Lecht, S., Lazarovici, P. Bioessays (2004)
- A Mechanism-Based Inactivator for Histone Demethylase LSD1. Culhane, J.C., Szewczuk, L.M., Liu, X., Da, G., Marmorstein, R., Cole, P.A. J. Am. Chem. Soc. (2006)
- Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. Avramovich-Tirosh, Y., Amit, T., Bar-Am, O., Zheng, H., Fridkin, M., Youdim, M.B. J. Neurochem. (2007)
- Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Sterling, J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., Miskolczi, I., Molnar, S., Rantal, F., Tamas, T., Toth, G., Zagyva, A., Zekany, A., Finberg, J., Lavian, G., Gross, A., Friedman, R., Razin, M., Huang, W., Krais, B., Chorev, M., Youdim, M.B., Weinstock, M. J. Med. Chem. (2002)
- Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. Yu, P.H., Davis, B.A., Durden, D.A., Barber, A., Terleckyj, I., Nicklas, W.G., Boulton, A.A. J. Neurochem. (1994)
- The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey. Andringa, G., Cools, A.R. J. Neural Transm. Suppl. (2000)
- The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Youdim, M.B., Amit, T., Falach-Yogev, M., Am, O.B., Maruyama, W., Naoi, M. Biochem. Pharmacol. (2003)
- Sequential amination/annulation/aromatization reaction of carbonyl compounds and propargylamine: a new one-pot approach to functionalized pyridines. Abbiati, G., Arcadi, A., Bianchi, G., Di Giuseppe, S., Marinelli, F., Rossi, E. J. Org. Chem. (2003)
- CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice. Groeneveld, G.J., van Muiswinkel, F.L., de Leeuw van Weenen, J., Blauw, H., Veldink, J.H., Wokke, J.H., van den Berg, L.H., Bär, P.R. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2004)
- Relationship between the hydrophobic physicochemical parameters and biological activity of some monoamine oxidase inhibitory drugs. Forgács, E., Magyar, K. Biochem. Mol. Biol. Int. (1994)
- Inhibition by aminoacetonitrile and propargylamine of glycine cleavage system from rat brain and liver mitochondria. Benavides, J., Croci, N., Strolin Benedetti, M. Biochem. Pharmacol. (1983)
- Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Youdim, M.B., Weinstock, M. Cell. Mol. Neurobiol. (2001)
- L-Deprenyl as an inhibitor of menadione-induced permeability transition in liver mitochondria. De Marchi, U., Pietrangeli, P., Marcocci, L., Mondovì, B., Toninello, A. Biochem. Pharmacol. (2003)
- Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity. Yu, P.H., Davis, B.A., Boulton, A.A. Biochem. Pharmacol. (1993)
- Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. Youdim, M.B., Bar Am, O., Yogev-Falach, M., Weinreb, O., Maruyama, W., Naoi, M., Amit, T. J. Neurosci. Res. (2005)
- Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. Kitani, K., Minami, C., Yamamoto, T., Maruyama, W., Kanai, S., Ivy, G.O., Carrillo, M.C. Ann. N. Y. Acad. Sci. (2001)
- Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Youdim, M.B., Fridkin, M., Zheng, H. Mech. Ageing Dev. (2005)
- Interaction of monoamine oxidase inhibitory drugs with some phospholipids. Szögyi, M., Cserháti, T. Journal of pharmaceutical and biomedical analysis. (1993)